TheraCryf PLC (TCF)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.20p
Buy
0.22p
0.00p (+0.00%)
Prices updated at 17 Dec 2025, 12:47 GMT
| Prices minimum 15 mins delay
Prices in GBX
Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Its pipeline is based on Sulforadex technology which includes synthetic and stabilized analogues of sulforaphane.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | 5.25 |
| 2022 | - |
| 2021 | - |
| 2020 | 74.70 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Price/Forward earnings (YTD)
-1.75
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2025 | -36.31 |
| 2024 | -67.93 |
| 2023 | -51.14 |
| 2022 | -24.76 |
| 2021 | -30.96 |
| 2020 | -71.25 |
| 2019 | -74.72 |
| 2018 | -57.39 |
| 2017 | -50.54 |
| 2016 | -80.76 |
| 2015 | -493.06 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2025 | 1.28 |
| 2024 | 1.31 |
| 2023 | 1.16 |
| 2022 | 1.04 |
| 2021 | 1.05 |
| 2020 | 1.16 |
| 2019 | 1.33 |
| 2018 | 1.10 |
| 2017 | 1.12 |
| 2016 | 1.04 |
| 2015 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
